Location History:
- Research Triangle Park, NC (US) (2014)
- Raleigh, NC (US) (2014)
Company Filing History:
Years Active: 2014
Title: Gary Martin Green: Innovator in Opioid Receptor Research
Introduction
Gary Martin Green is a notable inventor based in Research Triangle Park, North Carolina. He has made significant contributions to the field of pharmacology, particularly in the development of novel compounds for the treatment of opioid addiction. With two patents to his name, Green's work aims to provide new therapeutic options for those affected by addiction.
Latest Patents
Gary Martin Green holds two recent patents that focus on compounds serving as antagonists or inverse agonists of opioid receptors. The first patent details "Compounds as antagonists or inverse agonists of opioid receptors for treatment of addiction." This patent emphasizes innovative compounds that target one or more opioid receptors, along with the pharmaceutical compositions containing these compounds and the processes for their preparation. The second patent shares a similar focus: "Compounds as antagonists or inverse agonists at opioid receptors." It also analyzes novel compounds that engage with opioid receptors, cementing Green's role in advancing drug therapy in this critical area.
Career Highlights
Currently, Gary Martin Green is associated with GlaxoSmithKline LLC, a global leader in pharmaceuticals that fosters innovation and research in health solutions. His work at the company highlights his commitment to developing new therapies, particularly in combating the opioid addiction crisis.
Collaborations
Throughout his career, Gary has collaborated with esteemed colleagues such as David John Cowan and Andrew Lamont Larkin. Together, they have contributed to refining the understanding of opioid receptors and the potential benefits of targeting these pathways therapeutically.
Conclusion
In conclusion, Gary Martin Green's innovative work in the field of opioid receptors positions him as a key inventor in pharmaceutical advancements aimed at treating addiction. His patents reflect a deep understanding of the complexities within pharmaceutical chemistry, making him a valuable contributor to ongoing research and development efforts.